



WNTRESEARCH

Presentation av AdHoc data

Pernilla Sandwall, VD

5 januari 2023

Disclaimer

This company presentation (the "Company Presentation"), which is personal to the recipient, is issued by WntResearch AB (the "Company"). The Company Presentation has been prepared for information purposes only and is not to be relied upon in substitution for the exercise of independent judgement. The Company Presentation may not be reproduced, redistributed, passed on or published, in whole or in part, to any other person for any purpose. Unless otherwise stated, the Company is the source for all data contained in the Company Presentation. Such data is provided as at the date of this Company Presentation and is subject to change without notice. The Company Presentation (together with any further information which may be provided to the addressee) is made available on the condition that it is for use only by the addressee specified above for the sole purpose of evaluating the Company and shall not be passed on to any other person or copied or reproduced, copied, distributed, disclosed or published in whole or part and shall be immediately returned along with any other copies or destroyed at any time at the request of Company.

The Company Presentation is solely for your information and should not be relied upon and shall not confer rights or remedies upon, you or any of your employees, creditors, holders of securities or other equity holders or any other person. No representation or warranty, express or implied, is made by the Company or any of its directors, officers, employees, representatives, advisers or agents or any other person or entity as to the fairness, reasonableness, adequacy, accuracy or completeness of the information, statements or opinions, whichever its source, contained in this document (including any written or oral information made available to any interested party in connection thereto), and no liability whatsoever is accepted by any such person in relation to any such information or opinion. The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and its credit worthiness and does not purport to be all-inclusive or to contain all information that prospective investors may desire or that may be required to properly evaluate the business, prospects or value of the Company.

The information in this Company Presentation has not been independently verified. No representation or warranty, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information or opinions contained herein. The Company or any of their respective subsidiaries or affiliates or any of such person's directors, officers or employees, advisers or other representatives, accepts any liability whatsoever (whether in negligence or otherwise) arising, directly or indirectly, from the use of this Company Presentation or otherwise arising in connection therewith. The Company is under no obligation to submit further information. By receiving this Company Presentation and/or attending a presentation concerning the contents hereof you acknowledge that you will be solely responsible for your own assessment of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the Company.

This Company Presentation includes forward-looking statements. All statements other than statements of historical fact included in this Company Presentation, including, without limitation, those regarding the Company's financial position, business strategy, management plans and objectives for future operations are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance, achievements or industry results to be materially different from those expressed or implied by these forward-looking statements. Forward-looking statements speak only as of the date of this Company Presentation and Vator Securities and the Company expressly disclaim any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this Company Presentation as a result of any change in expectations or any change in events, conditions or circumstances on which these forward-looking statements are based. No representation is made that any of these forward-looking statements or forecasts will come to pass or that any forecast result will be achieved.


Vi har positiva och oväntade observationer i NeoFox studien



PRESSMEDDELANDEN

"Det är mycket tillfredsställande att de resultat vi fått i tidigare prekliniska studier nu också har observerats i vår kliniska studie. Att en effekt observerades redan efter tre veckors behandling är inte bara överraskande utan också mycket intressant"


Professor Tommy Andersson, grundare av och styrelsemedlem i WntResearch



Observationerna är både positiva och oväntade


- Positiva för att de visar mätbar effekt på cancer
- Oväntade för att de kunde mätas redan vid operation dvs efter 3 veckors behandling

Fas 2-studien NeoFox för patienter med tjocktarmscancer utan metastaser



* Patienter som genom CT-röntgen bedöms ha tjocktarmscancer i stadium II/III, kan gå med i studien

Observationerna är gjorda vid operationstillfället



* Patienter som genom CT-röntgen bedöms ha tjocktarmscancer i stadium II/III, kan gå med i studien

Statistiskt signifikanta observationer vid operation

Genom bedömning av förändringar på olika sätt:


1. TNM-klassificering
2. Spridning till omkringliggande nerver (perineural invasion, PNI)
3. Spridning till omkringliggande kärl (vaskulär invasion, V)

1) TNM-klassificering av cancer

- TNM-klassificeringen är internationellt vedertagen och anpassas till vilken typ av cancer som avses
- Klassificering och utbredningen av tjocktarmscancer bestäms genom:
 - T = tumörens invasion av tarmväggen och eventuell spridning till närliggande vävnad
 - N = spridning till närliggande lymfkörtlar
 - M = metastasering (spridning till andra delar av kroppen)
- Observationerna avser förändring av cancer från studiestart fram till operation:
 - *Downstaging* innebär en mindre utbredd cancer
 - *No change* innebär ingen förändring
 - *Upstaging* innebär en mer utbredd cancer

Foxy-5 behandling leder till mindre utbredd cancer

% patienter




2) och 3) spridning till omkringliggande nerver och kärl

- Spridning till omkringliggande nerver, sk perineural invasion (PNI)
- Spridning till omkringliggande kärl, sk vaskulär invasion (V)
- Observationerna avser om det finns spridning eller inte
 - *Denna information finns dock inte för riktigt alla patienter*

Fler patienter på Foxy-5 har ingen spridning av cancer till omkringliggande nerver

% patienter som saknar spridning




41%

fler patienter som behandlades med Foxy-5 hade ingen spridning av cancer till omkringliggande nerver

Skillnaden är statistiskt signifikant $p=0,0088$

Fler patienter på Foxy-5 har ingen spridning av cancer till omkringliggande kärl

% patienter som saknar spridning



38%

fler patienter som behandlades med Foxy-5 hade ingen spridning av cancer till omkringliggande kärl

Skillnaden är statistiskt signifikant $p=0,0097$

De positiva observationerna ger bra grund till vägen framåt för Foxy-5

- Observationerna
 - är både numeriskt stora och statistiskt signifikanta
 - gjordes på flera parametrar
 - ses redan efter 3 veckors behandling
 - indikerar en biologisk aktivitet
- Detta resulterar i
 - möjlighet att mäta effekt redan vid operation (jämfört med 2 år *efter* operation)
 - mindre kapitalbehov för att slutföra den pågående fas 2-studien NeoFox
 - potential för fler kliniska indikationer